Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Operating Margin: 2009-2025

Historic Operating Margin for Gyre Therapeutics (GYRE) over the last 14 years, with Sep 2025 value amounting to 22.66%.

  • Gyre Therapeutics' Operating Margin rose 605.00% to 22.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 11.22%, marking a year-over-year increase of 8370.00%. This contributed to the annual value of 15.28% for FY2024, which is 7454.00% up from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Operating Margin is 22.66%, which was up 179.39% from 8.11% recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Operating Margin high stood at 39.84% for Q3 2023, and its period low was -1,851.51% during Q1 2022.
  • Its 3-year average for Operating Margin is -13.78%, with a median of 16.61% in 2024.
  • Per our database at Business Quant, Gyre Therapeutics' Operating Margin tumbled by 149,855bps in 2021 and then skyrocketed by 187,824bps in 2023.
  • Gyre Therapeutics' Operating Margin (Quarterly) stood at -832.50% in 2021, then spiked by 81,037bps to -22.13% in 2022, then crashed by 31,540bps to -337.53% in 2023, then spiked by 33,991bps to 2.39% in 2024, then surged by 605bps to 22.66% in 2025.
  • Its last three reported values are 22.66% in Q3 2025, 8.11% for Q2 2025, and 10.30% during Q1 2025.